By Nigam Arora & Dr. Natasha Arora
Bud is part of a strategy of buying a great company when it suffers a temporary pullback. The Arora Report members took advantage of the drop in BUD stock when it fell on gender related boycott.
Breakout
Technically, BUD is breaking out. However, resistance is ahead. For this reason, BUD should be bought only on a pullback or break above the resistance zone of *** (To see the locked content, please take a 30 day free trial). The stock is trading at $62.71 as of this writing.
Zones
For those who are following the Good Way, the Buy Now rating is ***.
For those following the Best Way, the buy zone is ***.
The prior recommended quantity was ***. However, those buying now may consider ***.
The very long term target is $112 – $122.
What To Do Now
Those in the stock may consider continuing to hold but consider taking partial profits on a small quantity if BUD starts reaching the upper half of the resistance zone. To learn how to take partial profits, please see the “Taking Partial Profits” section of the Trade Management Guidelines.
Those not in the stock may consider following the parameters given above.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
